Genetically Engineered Animals, Drugs, and Neoliberalism: The Need for a New Biotechnology Regulatory Policy Framework

Genetically engineered (GE) animals that are meant for release in the wild could significantly impact ecosystems given the interwoven or entangled existence of species. Therefore, among other things, it is all too important that regulatory agencies conduct entity appropriate, rigorous risk assessmen...

Full description

Saved in:
Bibliographic Details
Published in:Journal of agricultural & environmental ethics 2017-12, Vol.30 (6), p.715-743
Main Author: Meghani, Zahra
Format: Article
Language:English
Subjects:
Agricultural biotechnology
Agricultural Economics
Animals
Biotechnology
Decision making
Drugs
Ecosystems
Education
Environmental impact
Ethics
Evolutionary Biology
Federal regulation
Genetic engineering
Neoliberalism
Philosophy
Plant Sciences
Regulatory agencies
Risk assessment
Theory of Medicine/Bioethics
Wildlife management
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genetically engineered (GE) animals that are meant for release in the wild could significantly impact ecosystems given the interwoven or entangled existence of species. Therefore, among other things, it is all too important that regulatory agencies conduct entity appropriate, rigorous risk assessments that can be used for informed decision-making at the local, national and global levels about the release of those animals in the wild. In the United States (US), certain GE animals that are intended for release in the wild may be regulated as new animal drugs by the Food and Drug Administration. This paper argues that the decision to treat them as new animal drugs is attributable to the influence of neoliberalism on the US biotechnology regulatory policy framework. The case is made that there should be public democratic deliberations and decision-making about the values and concerns that should guide the nation’s biotechnology regulatory policy paradigm, including the risk assessment process for GE animals meant for release in the wild.
ISSN:1187-7863
1573-322X
DOI:10.1007/s10806-017-9696-1